Search results
Results from the WOW.Com Content Network
Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.
The U.S. Food and Drug Administration (FDA) granted orphan drug designations in 2010 and 2020, [9] [10] and breakthrough therapy designation in 2016, on the basis of preliminary data from the phase II trial.
Garadacimab is an experimental human monoclonal antibody under investigation for the treatment of hereditary angioedema. [1] Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
The FDA earlier granted the application for risdiplam fast track, priority review, and orphan drug designations. [6] [9] [11] Genentech was also awarded a rare pediatric disease priority review voucher. [6] The European Medicines Agency (EMA) awarded risdiplam a priority medicine designation in 2018 [11] [19] [20] and an orphan drug designation ...
Get today's best rates on high-yield FDIC-insured savings accounts to more quickly grow your everyday money, build an emergency reserve or save for a successful retirement.
Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7] [8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
The US Food and Drug Administration (FDA) prescription label for palopegteriparatide includes warnings for a potential risk of risk of unintended changes in serum calcium levels related to number of daily injections and total delivered dose, serious hypocalcemia and hypercalcemia (blood calcium levels that are too high), osteosarcoma (a rare bone cancer) based on findings in rats, orthostatic ...
Decitabine/cedazuridine was approved for medical use in the United States and Canada in July 2020, [7] [8] [9] [12] and in the European Union in September 2023. [6]The U.S. Food and Drug Administration (FDA) granted the application of decitabine combined with cedazuridine priority review and orphan drug designation.